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ABSTRACT  
 
Background: People who inject drugs (PWID) are at the greatest risk of hepatitis C virus (HCV) 
infection, yet are often denied immediate treatment due to fears of on-going risk behaviour. Our 
principle objective was to examine evidence of continued injecting drug use among PWID 
following  successful treatment for HCV and attainment of a sustained viral response (SVR). 
Methods: PWID who attained SVR between 1992 and June 2012 were selected from the National 
Scottish Hepatitis C Clinical Database.  Hospitalisation and mortality records were sourced for 
these patients using record-linkage techniques.  Our primary outcome variable was any 
hospitalisation or death which was indicative of injecting drugs post-SVR.   
Results: The cohort comprised 1170 PWID (mean age at SVR 39.6y; 76% male).  The Kaplan 
Meier estimate of incurring the primary outcome after three years of SVR was 10.6% (95% CI, 
8.8-12.8) After adjusting for confounding, the risk of an injection related hospital episode or 
death post-SVR was significantly increased with advancing year of SVR: AHR:1.1 per year (95% 
CI, 1.0-1.2), having a pre-SVR acute alcohol-related hospital episode: AHR:1.8 (95% CI, 1.3 – 
2.6), and having a pre-SVR opiate or injection-related hospital episode: AHR:2.6 (95% CI, 1.9 – 
3.7).   
Conclusion: Despite attaining the optimal treatment outcome, these data indicate that an 
increasing significant number of PWID continue to inject post-SVR at an intensity which leads to 
either hospitalisation or death and potential increased risk of reinfection.  
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1. Introduction  
 
It is well established that people who inject drugs (PWID) are at the greatest risk of hepatitis C 
virus (HCV) infection.   Globally, there are an estimated 16 million PWID who are currently 
injecting (Mathers et al., 2008), of which 10 million are estimated to have been infected with 
HCV (Nelson et al., 2011).  Chronic HCV infection is a major cause of liver related morbidity and 
mortality, but can be cleared with antiviral treatment and establishment of sustained viral 
response (SVR).  Currently, there is low uptake of HCV antiviral treatment among PWID which 
likely relates to concerns of adherence to, and reinfection post, treatment (Martin et al., 2013; 
Iversen and Maher 2012). Regardless, a recent meta-analysis found treatment outcomes to be 
acceptable and risk of HCV reinfection to be relatively low among PWID, albeit based on only a 
few small scale studies conducted in clinical and harm reduction settings (Aspinall et al., 2013).  
Modelling work has further demonstrated that treating PWID is cost-effective and has the 
potential to reduce HCV transmission and prevalence in this population (Martin et al., 2011; 
Martin et al., 2013).  Therefore, recommendations state that treatment is not to be withheld 
from an individual based on injection status alone (EASL, 2014).  
After being deemed one of the greatest public health challenges of our time, HCV was made a 
priority by the Scottish Government and a comprehensive Action Plan was formulated to curb 
the predominately injecting-related epidemic (Chisholm, 2004; Scottish Government, 2008).  As 
a result, the overall number of people initiated on antiviral therapy in Scotland more than 
doubled between 2007 and 2010 with ~1000 now treated per year and the vast majority 
(>80%) of these report having ever injected drugs (HPA, 2013).   
Given this recent, and also anticipated future upscale in treatment provision among PWID, a 
better understanding is needed of the injecting risk behaviours, and potential for reinfection, 
post-SVR.  Our principle objective, therefore, was to establish evidence, and predictors, of 
continued engagement in injection drug use post-SVR using a record-linkage approach involving 
both HCV treatment and injecting-related hospitalisation data for a large nationally 
representative cohort of over 1000 PWID. 
2. Methods 
2.1 Study Population, data sources and linkage procedure 
This paper utilised a retrospective cohort of Scottish PWID derived from the HCV Clinical 
Database, using data linked from four, national databases.  Health Protection Scotland (HPS) 
holds and maintains individual patient data for all HCV diagnosed persons who attended a 
specialist centre for HCV treatment and management across Scotland, referred to as the HCV 
Clinical Database.  This database includes information on patient demographics, virology, 
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treatment episodes, epidemiological exposures, and liver disease investigations. Inclusion 
criteria for the study was a history of injection drug use, SVR attained by June 2012, and 
sufficient identifiers for record-linkage (n=1,259). To enable further database linkage 
(described below), the HCV Clinical Database was first linked to the Scottish HCV Diagnosis 
Database, as previously described (Innes, et al., 2011); this linkage also allowed for scrutiny of 
patient record accuracy, such that patients were dropped if flaws in treatment records were 
detected (e.g. nonsensical diagnosis and treatment dates).  
Hospital episode data were obtained by sourcing Information Services Division (ISD) Scotland’s 
Scottish Morbidity Records (SMR) 01 and 04, which provide general, non-obstetric hospital 
discharge data and psychiatric hospital admissions data respectively.  Hospital episodes are 
coded using the World Health Organisation’s International Classification of Disease (ICD) Ninth 
Revision for all hospitalisations prior to 1996, and Tenth Revision for hospitalisations 
thereafter.  SMR records include six possible diagnostic fields, all of which were used in analysis. 
Mortality data were obtained through sourcing deaths registrations collated by National 
Records of Scotland.  Date, and up to eleven causes of death are recorded for each registered 
death using ICD-9 and ICD-10 codes.   
2.2 Linkage Procedure  
ISD Scotland annually link the Scottish HCV Diagnosis Database to SMR and deaths data. This 
probabilistic linkage technique is estimated to have a rate of false positives or false negatives 
under 5% (Kendrick & Clarke, 1993); the probabilistic linkage has also been previously 
described (McDonald et al., 2008). 
Thereafter, this linked dataset, containing SMR/deaths data on all HCV diagnosed persons, was 
transferred to HPS and combined with the Clinical and Diagnosis dataset, via the HCV diagnosis 
database record number, to enable extraction of hospitalisation and mortality data for all those 
who had attended a specialist clinic for HCV. The final linked dataset included all relevant 
demographic, behavioural, morbidity and mortality data for 1170 Scottish PWID who have 
received antiviral treatment for HCV and attained SVR in the over 20 year period between 1992 
and June 2012.   
2.2 Outcome Measures  
The outcome variable of interest was defined as a hospital event or death indicative of injection 
drug use.  This was identified using the following International Classification of Disease (ICD) 
codes present in the any diagnosis field indicating hospital discharge diagnosis or death.  The 
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relevant outcome codes comprised opiate-related: mental and behavioural disorders due to 
opiate misuse (ICD-10: F11), poisoning due to opium (ICD-9: 965.0; ICD-10: T40.0), poisoning 
due to heroin (ICD-10: T40.1),  accidental poisoning due to heroin (ICD-9: E8500; ICD-10: X42.4) 
accidental poisoning due to opium (ICD-10: X42.9), intentional self-poisoning by exposure to 
opium (ICD-10: X62.9),  opiate dependence (ICD-9: 3040),  non-dependent opiate use (ICD-9: 
3055), finding opiates in blood (ICD-10: R781),and injection-related as defined in previous 
literature: endocarditis (ICD-9: 421.0; ICD-10: I33), deep vein thrombosis (ICD-9: 451, 453 ; ICD-
10: I80), cellulitis /abscesses (ICD-9: 682; ICD-10: L02, L03), (Lloyd-Smith et al., 2008; Irish et al., 
2007).  
2.3 Explanatory variables  
Behavioural and demographic exposure variables of interest were recorded for each patient 
pre-SVR and were obtained from clinical and SMR records.   
Behavioural variables included presence of an acute alcohol intoxication-related hospital 
episode, and history of injection indicative hospital episode pre-SVR (using the above listed 
codes).  Alcohol intoxication-related hospital episodes have been previously defined and include 
hospital episodes due to problems related to lifestyle alcohol use (ICD-10: Z72.1), mental and 
behavioural disorders due to use of alcohol (ICD-10: F10), toxic effect of alcohol (ethanol, 
methanol, unspecified)(ICD-9: 980.0, 980.1, 980.9; ICD-10: T51.0, T51.1, T51.9), blood alcohol 
level 100-240+/ 100 ml (ICD-9: 790.3; ICD-10: Y90.5 – Y90.9), evidence of alcohol involvement 
determined by level of intent (ICD-10: Y91), finding of alcohol in blood (ICD-10: R78.0), poisoning 
by and exposure to alcohol(ICD-9: E8600-02, E8609; ICD-10: X45, X65, Y15), alcohol deterrents 
(ICD-10: Y57.3), alcohol abuse counselling and surveillance (ICD-10: Z71.4), non-dependent 
alcohol abuse (ICD-9: 305.0).  
Additional explanatory variables for each PWID included age at SVR, gender, year of SVR (date 
of SVR was defined as negative HCV RNA reading 24 weeks post-treatment completion), 
presence of cirrhosis at treatment initiation. Age at SVR was categorised into three groups (<30, 
30-44, ≥45).  Year of SVR was categorised for descriptive analysis (1992-2004, 2005-2012), and 
kept continuous for statistical modelling.  Patients who were cirrhotic at time of treatment 
initiation were identified by the Clinical Database, based on a combination of (i) clinical 
examination; (ii) radiology (ultrasound, transient elastography, computed tomography, or 
magnetic resonance imaging); or (iii) liver biopsy, as previously described (Innes, et al., 2012).  
2.4 Statistical Analyses 
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All statistical analyses, data storage, and manipulation were conducted using STATA version 12 
(College Station, TX, USA).  
2.4a Analysis of first-time opiate or injection related hospital event or death 
Firstly, Kaplan Meier survival estimates were used to calculate the estimated proportion of the 
cohort who had an opiate or injection-related hospital episodes or death at three years post-SVR 
attainment.  
Secondly, we used multivariate Cox regression to determine predictors for the first time to first 
injecting related hospital episode or death.  Time at risk was calculated in person years (PY) 
from date of SVR attainment to first injection-related hospital episode, death, or end of follow up 
(30th June 2012).  Adjusted hazard-ratios of an opiate or injection-related hospital episode or 
death post-SVR were generated using a multivariate Cox regression analysis, with inclusion of 
all covariates irrespective of univariate association. 
2.4b Analysis of multiple opiate or injection related hospital events and/or death 
Risk of multiple hospital episodes associated with behavioural and demographic covariates 
were analysed using Poisson regression.  Time at risk was censored at either death of end of 
follow up(30 June 2012), but was not censored for periods in hospital.  Crude, unadjusted rates 
of multiple hospital episodes due to opiate or injection-related reasons were measured per 100 
PY of follow-up.   
3. Results 
3.1 Sample Characteristics (Table 1) 
Table 1 displays the demographic and behavioural characteristics of the cohort with regards to 
injection indicative hospital episodes or deaths post-SVR.  The average age at SVR was 39.6 
years (standard deviation ± 8.2 years; range 19.0-67.7 years), and the majority were male 
(76%).  The majority of the cohort (76%) attained SVR between 2006- June 2012.  37% of the 
cohort had been in hospital for an opiate or injection related episode pre-SVR. 13% had at least 
one opiate or injection-related hospital episode or death during an average follow up of 4.1 
years. 
Kaplan Meier estimates of incurring our primary outcome at three years are presented in Table 
1. The overall estimate was 10.6% (95%CI 8.8-12.8%).  This proportion varied by 
demographic/behavioural factors and was highest among those with an opiate or injection-
related hospital event/death pre-SVR (19.2%, 95%CI 15.2% - 24.2%).  While the lowest 
estimated proportion of opiate or injection-related hospital event or death was observed for 
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those who had attained SVR between 1992-2000 (2.2%, 95% CI 0.3-14.7%).  A Kaplan Meier 
curve of those PWID who remain free of injection related hospitalisation over 8 years is 
illustrated in Figure 1.  
3.2 First-time opiate or injection-related hospital episode post-SVR 
The overall crude rate of injection indicative hospital episodes post-SVR was 3.12 per 100 PY 
(Table 2), with the highest incidence rate noted in PWID who had an opiate or injection-related 
hospital episode pre-SVR (6.04 per 100 PY).  Within the respective exposure variable groups, 
those aged 30 or younger at SVR had the highest incidence (3.92 per 100 PY) when compared 
with those aged 45 and older, along with females (3.75 per 100 PY), and those with an alcohol 
intoxication-related hospital episode pre-SVR (5.7 per 100 PY).  
In univariate analysis, all covariates with the exception of sex and cirrhosis at treatment 
initiation were associated with an injection indicative hospital episode or death post-SVR (Table 
2).  Significant predictors of an opiate or injection-related hospital episode or death post-SVR 
identified in multivariate Cox regression include: year of SVR (AHR: 1.07, 1.01 – 1.14), alcohol-
related hospital episode pre-SVR (AHR: 1.83, 1.29 – 2.60), and opiate or injection-related 
hospital episode pre-SVR (AHR: 2.59, 1.84 – 3.64).  Age at SVR did not retain its significance 
after adjusting for other covariates. 
3.3 Multiple opiate and injection-related hospital episodes post-SVR 
There were a total of 236 post-SVR injection indicative hospital episodes and 11 (1%) opiate or 
injection-related deaths among 1170 PWID, ranging from 0-8 episodes per patient (Table 3).  In 
univariate analysis, all factors with the exception of cirrhosis at treatment initiation were 
associated with incidence of injection indicative hospital episodes or death post-SVR. In 
multivariate analysis significant predictors of increased incidence of opiate or injection related 
hospital episodes post-SVR include sex, history of alcohol intoxication-related hospital episode 
pre-SVR, and history of opiate or injection-related hospital episode pre-SVR. When compared to 
males, females had an increased incidence of opiate or injection-related hospital episodes post-
SVR (adjusted incidence rate ratio [AIRR]: 1.32, 1.00 – 1.73).  History of an alcohol intoxication-
related hospital episode (AIRR: 2.59, 1.99 – 3.36), and of opiate of injection-related hospital 
episode (AIRR: 2.95, 2.24 – 3.89) were shown to significantly predict increased incidence of 
injection indicative hospital episodes/death post-SVR after adjusting.  
4. Discussion 
 
With highly effective but costly HCV treatments on the horizon, and potential demand for 
treatment to increase, particularly among the population who injects drugs, it is essential that 
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the behaviours which pose a risk of re-infection post-SVR are well understood.  There have been 
a few small studies examining engagement in injection drug use post-HCV antiviral treatment 
induced SVR, and these have relied on participation and accurate self-report by PWID, and have 
varied in respect of recruitment setting; thus, rates of continued injection drug use ranged 
considerably from 12-100% post-SVR (Marco et al., 2013; Page et al., 2009).  Results obtained 
from our study were derived from a large anonymous record-linkage exercise of routine 
administrative data on all PWID undergoing therapy, thereby increasing cohort size and 
avoiding participation bias.  This study estimated that 10.6% of the Scottish cohort of 1170 
PWID had been in hospital for or had died from an opiate or injection-related cause in the first 
three years post-SVR, which suggests that in excess of this proportion were injecting drugs 
during the early years following successful therapy.  
A relatively low risk of HCV reinfection post-SVR has so far been reported from studies 
involving PWID (pooled rate of 2 per 100 PY from recent meta-analysis), however these were 
predominately centred in settings with considerable harm reduction support and thus may not 
reflect the wider injecting population (Aspinall et al., 2013).  Risk of HCV reinfection has 
certainly been demonstrated to be far higher, by thirteen-fold, among people who report 
actively injecting drugs post-SVR when compared with those who do not (Marco et al., 2013).  
The result here show that the risk of an opiate or injection=related hospital episode or death 
was rising over time with increasing year of SVR attainment likely reflects the expansion of 
treatment among the population who have ever injected drugs in Scotland, having increased 
nine-fold between 2001-2 and 2009-10 (McDonald et al., 2014), and broadening to not just 
those who have injected in the distant past, but to those who have injected recently and 
continue to do so.  The expansion of therapy in this population group was consistent with the 
aims of the Scottish Government’s Action Plan on HCV and now also the European and Global 
guidelines which endorse treatment of patients with ongoing drug use.  Thus, our proxy 
injection indicative hospitalisations/deaths data would suggest that reinfection post therapy 
will rise in Scotland, and could well increase in other countries as they scale-up therapy in their 
PWID populations.  
Individuals found to have been hospitalised for either an injection indicative or alcohol-related 
cause prior to therapy, being 30% of our cohort, were at significantly increased risk of being 
admitted or died post-therapy or an opiate/injection-related cause. So the hospitalisation data 
may help point to a group who are particularly prone to re-engaging with risk behaviours.  
Likewise, those younger compared to older in age, although not significant in multivariate 
analysis, were more likely to engage in injecting practices post-treatment, as indicated by an 
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estimated 15% and 7% of those aged under 30 and over 45 years, respectively, having been in 
hospital or died from an opiate/injection-related cause within three years of SVR attainment.  
There are some limitations to our study.  Using hospital diagnosis records does not capture the 
total amount of injecting occurring post-SVR.  Hospitalisations represent extreme cases of 
injecting (poisoning, overdose, severe injury), and thus likely underestimate the extent to which 
PWID are continuing to inject, as most injecting episodes do not result in hospitalisation.  
Additionally, utilising hospitalisation records relies on using ICD codes as a measure of current-
diagnosis.  ICD codes indicating opiate use or injection drug use do not always necessarily 
indicate acute injecting episodes and could thus include historical events, or non-injecting 
opiate abuse, which could have caused an overestimation of the true rate of hospitalisation for 
post-SVR injection drug use.   
This study did not explore engagement in other reinfection risk factors (e.g. tattooing, sexual 
practices) post-SVR, although these are unlikely to pose the same population risk as continued 
injecting drug use.  Further, we did not consider specifically the risk of reinfection here, as it 
required follow-up laboratory data on HCV RNA testing, but that is now the focus of a 
subsequent study.  This risk behaviour research has, however, informed the need to fully 
understand the extent of testing and diagnosis of PWID post-SVR.  Additionally, SVR patients 
account for roughly 60% of the overall treated population, and we therefore did not report on 
the behaviours of remaining 40% who were treated and did not attain the optimal outcome 
(Innes, et al., 2012). This leaves scope for further research using such a comparison group. 
Implications and Recommendations  
While treatment induced viral clearance is well known to improve health outcomes, it does not 
completely remove the risk of liver related morbidity and mortality.  Lifestyle factors- that can 
either accelerate the rate of liver disease progression (e.g. alcohol consumption) or cause re-
infection- pose a significant excess risk of liver disease among patients who have attained SVR 
(Innes, et al., 2013).This study indicates that the risk of HCV reinfection post-SVR through 
continued injection drug use could increase as treatment is expanded and scaled up in 
populations who inject drugs.  Therefore for patients who successfully complete treatment and 
would ordinarily be discharged from care, continued monitoring with RNA testing would be 
advised for those with on-going risk behaviour, in line with recent European guidelines (EASL, 
2014).  Harm reduction interventions aimed at reducing the risk of HCV transmission should 
continue to be promoted once treatment ceases.  
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Table 1.Description of cohort of 1,170 PWID who attained a sustainedviral response (SVR) in Scotland, 
1992-2012. 
 
Abbreviations; SVR, sustained viral response; CI, confidence interval 
  
Characteristics N(%) Opiate or injection 
related hospital 
episode/death post-
SVR, n (%N) 
Estimated proportion of 
opiate or injection hospital 
episodes/deaths at 3 years 
post-SVR % (95% CI) 
 
Total 1170 (100) 149 (13) 10.59 (8.75 – 12.79) 
Age at SVR  
<30 
30-44 
  ≥45 
 142 (12) 
738 (63) 
290 (25) 
    23  (16) 
103(14) 
23(8) 
13.71 (8.53 – 21.62) 
11.28 (8.93 – 14.21) 
  7.19 (4.50 – 11.39) 
Sex  
    Male 
    Female 
889 (76) 
  281 (24) 
104 (12) 
   45 (16) 
10.26 (8.20 – 12.80) 
11.65 (8.07 – 16.66) 
Year of SVR  
    1992-2000   45   (4)   8  (18) 2.22 (0.32 – 14.75) 
    2001-2005 236 (20)  48 (20) 8.50 (5.57 – 12.86) 
    2006-2012 889 (76)  93 (10) 12.03 (9.67 – 14.93) 
Cirrhosis diagnosis at treatment initiation  
    No 
    Yes 
1081 (92) 
    89   (8) 
137 (13) 
12 (13) 
10.28 (8.40 – 12.56) 
14.65 (8.05 – 25.73) 
Alcohol intoxication-related hospital episode pre-SVR 
    No 
    Yes 
  912 (78) 
  258 (22) 
   98 (11) 
   51 (20) 
8.69 (6.84 – 11.02) 
17.58 (12.81 – 23.87) 
Opiate or injection-related hospital episode pre-SVR  
    No 
    Yes 
  743 (63) 
  427 (37) 
   63  (8) 
   86 (20) 
6.04 (4.38 – 8.31) 
19.24 (15.22 – 24.16) 
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Covariate Person 
Years  
Unadjusted crude rate 
per 100 PY (95% CI) 
Opiate or injection-related hospital episode/death post-SVR 
Univariate 
(HR, 95%CI) 
p-value Multivariate  
(AHR, 95% CI) 
 
p-value 
Study 
Population 
4764 3.12 (2.66 – 3.67)    
Age at SVR   
<30  586 3.92 (2.61 – 5.90) 2.07 (1.17 – 3.66)   0.013 1.51 (0.83 – 2.73)   0.179 
30-44 3023 3.41 (2.81 – 4.13) 1.65 (1.02 – 2.67) 
 
  0.041 1.48 (0.93 – 2.35)   0.099 
  ≥45 1155 1.99 (1.32 – 2.99) 1.00 (Baseline)  1.00 (Baseline)  
Gender     
Male  
Female 
   3564 2.92 (2.41 – 3.54) 1.00 (Baseline)  1.00 (Baseline)  
   1200  3.75 (2.89 – 5.02) 1.29 (0.91 – 1.83)   0.155 1.28 (0.90 – 1.83) 0.164 
Year of SVR 1.10 (1.03 – 1.16)   0.006 1.07 (1.01 – 1.14) 0.025 
Cirrhosis diagnosis at time of treatment initiation    
 No   4376 3.13 (2.64 – 3.70) 1.00 (Baseline)  1.00 (Baseline)  
Yes     388 3.09 (1.76 – 5.45)     1.05 (0.58 – 1.90)   0.876 1.03 (0.56-1.89) 0.966 
Alcohol intoxication-related hospital episode pre-SVR    
No   3864 2.54 (2.08 – 3.09) 1.00 (Baseline)  1.00 (Baseline)  
Yes     900 5.67 (4.31 – 7.46) 2.17 (1.54 – 3.05) <0.001 1.83 (1.29 – 2.60) 0.001 
Opiate or injection-related hospital episode pre-SVR  
No   3342 1.88 (1.47 – 2.41) 1.00 (Baseline)  1.00 (Baseline)  
Yes   1422 6.04 (4.90 – 7.47) 3.08 (2.22 – 4.27) <0.001 2.59 (1.84 – 3.64) <0.001 
      
Table 2.Risk of firstopiate or injection-related hospital episode or death among 1170 PWID who 
attained SVR in Scotland, 1992-2012. 
Abbreviations; SVR, sustained viral response; HR, hazard ratio; AHR, adjusted-hazard ratio; CI, confidence interval 
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Covariate N PY  Unadjusted crude rate 
per 100 PY (95% CI) 
Opiate or injection-related hospital episode/death post-SVR 
  Univariate (IRR, 
95%CI) 
p-
value  
Multivariate 
(AIRR, 95%CI) 
p-value  
Study 
Population 
236  5319  22.05 (29.83 – 23.35)   
Age at SVR     
<30   37 771   22.97 (29.83 – 26.62) 1.77 (1.13 – 2.79) 0.012 1.32 (0.83 – 2.09) 0.239 
30-44 160 3456  21.62 (20.12 – 23.22) 1.48 (1.04 – 2.11) 0.027 1.22 (0.85 – 1.74) 0.280 
 ≥45  39 1092  22.79 (20.12 – 25.81) 1.00 (Baseline)  1.00 (Baseline)  
Gender 
Male 159 3977  22.43 (21.00 – 23.95)  1.00 (Baseline)  1.00 (Baseline)  
Female  77 1342  20.95 (18.64 – 23.55)  1.48 (1.13 – 1.95) 0.005 1.32 (1.00 – 1.73)  0.048 
Year of SVR   1.05 (1.01 – 1.08) 0.015 1.03 (0.99 – 1.07) 0.107 
Cirrhosis diagnosis at treatment initiation 
No 213 4849   22.34 (21.04 – 23.71) 1.00 (Baseline)  1.00 (Baseline)  
Yes   23 470    19.15 (15.58 – 23.54)  1.24 (0.81 – 1.91) 0.327 1.03 (0.66 – 1.60) 0.894 
Alcohol intoxication-related hospital episode pre-SVR 
No 111 4223  21.64 (20.29 – 23.09) 1.00 (Baseline)  1.00 (Baseline)  
Yes 125 1096    23.63 (20.92 – 26.69)  2.85 (2.19 – 3.71) <0.001 2.59 (1.99 – 3.36) <0.001 
Opiate or injection related hospital episode pre-SVR 
No 88 3621  20.54 (19.12 – 22.07)  1.00 (Baseline)  1.00 (Baseline)  
Yes 148 1698   25.27 (22.99 – 27.78) 3.79 (2.89 – 4.97) <0.001 2.95 (2.24 – 3.89) <0.001 
N, Number of observed hospital episodes; PY, person years (does account for time spent in hospital); Rate, fitted 
number of hospital episodes per 100 person-years; SVR, sustained viral response; IRR, incidence rate ratio; AIRR, 
adjusted-incidence rate ratio; CI, confidence interval 
Table 3.Incidence and risk of multiple opiate or injecting-related hospital episodes among 1170 
PWID who attained SVR in Scotland, 1992-2012. 
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Figure1: Kaplan Meier Curve estimating the proportion of patients remaining free of in 
injection-related hospitalisation among 1170 PWID who attained SVR in Scotland, 1992-2012. 
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